论文部分内容阅读
目的:分析及探索针对支气管哮喘患者以孟鲁司特钠、布地奈德联合用药治疗的疗效。方法:选择本院呼吸二科2013年1月-2016年12月间接收的患支气管哮喘的200例患者,随机分成2组:对照组共100例,在常规治疗的基础上给予布地奈德辅助治疗;治疗组共100例,在对照组基础上,再给予孟鲁司特钠联合治疗。治疗结束后评估及比较2组的临床疗效,且观察患者的肺功能相关指标变化。结果:治疗组治疗后的总有效率(98%)明显高于对照组的81%(P<0.05);且治疗组治疗后的FEV_1/FVC%、PEF指标水平与对照组相比更高,差异有统计学意义(P<0.05)。结论:针对支气管哮喘患者以孟鲁司特钠、布地奈德联合用药治疗疗效显著,可有效改善肺功能,值得临床推广。
Objective: To analyze and explore the efficacy of montelukast and budesonide combination therapy in patients with bronchial asthma. Methods: A total of 200 patients with bronchial asthma received from January 2013 to December 2016 in our hospital were randomly divided into 2 groups: a control group of 100 patients received budesonide on the basis of routine treatment Treatment; a total of 100 cases of treatment group, on the basis of the control group, montelukast sodium combined treatment. After the treatment, the clinical efficacy of the two groups was evaluated and compared, and the changes of pulmonary function related indexes were observed. Results: The total effective rate (98%) in the treatment group was significantly higher than that in the control group (81%) (P <0.05). The FEV 1 / FVC% and PEF index of the treatment group were higher than those in the control group The difference was statistically significant (P <0.05). Conclusion: The treatment of patients with bronchial asthma with montelukast sodium and budesonide has significant curative effect, which can effectively improve pulmonary function and deserve clinical promotion.